Natriuretic peptides and the prevalence of congestive heart failure in patients with pacemakers

Aim The aim of the study was to investigate the diagnostic potential of natriuretic cardiac peptide measurement in the context of left ventricular dysfunction and comorbidities in a pacemaker population. Material and methods Ninety‐five consecutive patients with pacemakers were included in the study. All patients underwent echocardiography and were asked to complete the Minnesota Living with Heart Failure Questionnaire (MLHFQ). Brain natriuretic peptide (BNP), N‐terminal proatrial natriuretic peptide (N‐ANP) and atrial natriuretic peptide levels in plasma were measured. Results Twenty‐six percent of patients had reduced systolic left ventricular function; only 16 patients had a history of congestive heart failure. BNP was abnormally elevated in 64%, N‐BNP in 72% and N‐ANP in 96% of patients. Both BNP ( r = 0·30; P < 0·01) and N‐ANP ( r = 0·39; P < 0·0005) correlated with MLHFQ. The strongest correlation was found between N‐ANP and the ejection fraction ( r = 0·6; P < 0·0001). Patients were stratified in a high‐risk group and a low risk‐group according to their N‐ANP (N‐ANP > 5000 fmol L −1 ; n = 63 and N‐ANP < 5000 fmol L −1 , n = 32) and BNP levels (BNP > 400 pg mL −1 ; n = 17 and BNP < 400 pg mL −1 , n = 78). N‐ANP was correlated with hypertension ( P < 0·003) and atrial fibrillation ( P < 0·03), and BNP with mitral insufficiency ( P < 0·002). Conclusions Cardiac natriuretic peptides are markedly elevated in the majority of patients with pacemakers. The prognostic significance of BNP and N‐ANP in left ventricular dysfunction warrants close follow‐up schedules.